lyra-10q_20210630.htm
--12-31 false 0001327273 2021 Q2 false false false false 2021 0 P4Y 0 2020-04-30 2024-06-30 0 0 0 0 0 0 P5Y8M12D P6Y P6Y P6Y P7Y8M12D P8Y P6Y8M12D P8Y P1Y9M18D 0001327273 2021-01-01 2021-06-30 xbrli:shares 0001327273 2021-08-02 iso4217:USD 0001327273 2021-06-30 0001327273 2020-12-31 iso4217:USD xbrli:shares 0001327273 2021-04-01 2021-06-30 0001327273 2020-04-01 2020-06-30 0001327273 2020-01-01 2020-06-30 0001327273 us-gaap:RedeemableConvertiblePreferredStockMember 2020-03-31 0001327273 us-gaap:CommonStockMember 2020-03-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001327273 us-gaap:RetainedEarningsMember 2020-03-31 0001327273 2020-03-31 0001327273 us-gaap:RedeemableConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001327273 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001327273 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001327273 us-gaap:CommonStockMember 2020-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001327273 us-gaap:RetainedEarningsMember 2020-06-30 0001327273 2020-06-30 0001327273 us-gaap:CommonStockMember 2021-03-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001327273 us-gaap:RetainedEarningsMember 2021-03-31 0001327273 2021-03-31 0001327273 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001327273 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001327273 us-gaap:CommonStockMember 2021-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001327273 us-gaap:RetainedEarningsMember 2021-06-30 0001327273 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001327273 lyra:SeriesCRedeemableConvertiblePreferredStockMember 2020-01-01 2020-06-30 0001327273 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001327273 us-gaap:CommonStockMember 2019-12-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001327273 us-gaap:RetainedEarningsMember 2019-12-31 0001327273 2019-12-31 0001327273 us-gaap:RedeemableConvertiblePreferredStockMember 2020-01-01 2020-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001327273 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001327273 us-gaap:CommonStockMember 2020-12-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001327273 us-gaap:RetainedEarningsMember 2020-12-31 0001327273 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001327273 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001327273 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-06-30 0001327273 us-gaap:IPOMember us-gaap:CommonStockMember 2020-05-05 2020-05-05 0001327273 us-gaap:OverAllotmentOptionMember us-gaap:CommonStockMember 2020-05-05 2020-05-05 0001327273 us-gaap:IPOMember us-gaap:CommonStockMember 2020-05-05 0001327273 us-gaap:CommonStockMember 2020-05-05 2020-05-05 lyra:Patient 0001327273 2020-03-11 2020-03-11 0001327273 lyra:LianBioAgreementMember 2021-05-31 2021-05-31 0001327273 lyra:ClinicalSupplyAgreementMember 2021-05-31 0001327273 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001327273 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001327273 us-gaap:EquipmentMember 2021-06-30 0001327273 us-gaap:EquipmentMember 2020-12-31 0001327273 lyra:ComputerSoftwareAndEquipmentMember 2021-06-30 0001327273 lyra:ComputerSoftwareAndEquipmentMember 2020-12-31 0001327273 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001327273 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001327273 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001327273 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001327273 us-gaap:ConstructionInProgressMember 2021-06-30 0001327273 us-gaap:ConstructionInProgressMember 2020-12-31 0001327273 2020-05-05 lyra:Vote 0001327273 us-gaap:CommonStockMember 2020-05-05 0001327273 srt:DirectorMember us-gaap:CommonStockMember 2020-05-05 2020-05-05 0001327273 2021-05-11 2021-05-11 0001327273 lyra:OpenSalesAgreement2021ATMMember 2021-05-11 2021-05-11 0001327273 lyra:OpenSalesAgreement2021ATMMember 2021-01-01 2021-06-30 0001327273 us-gaap:EmployeeStockOptionMember 2021-06-30 0001327273 us-gaap:EmployeeStockMember 2021-06-30 0001327273 lyra:SeriesCRedeemableConvertiblePreferredStockMember us-gaap:WarrantMember 2021-01-01 2021-06-30 0001327273 us-gaap:IPOMember 2020-05-31 0001327273 lyra:TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001327273 lyra:TwentyThousandTwentyIncentiveAwardPlanMember 2020-04-30 0001327273 lyra:TwentyThousandTwentyIncentiveAwardPlanMember 2020-04-01 2020-04-30 xbrli:pure 0001327273 lyra:TwentyThousandTwentyIncentiveAwardPlanMember 2021-06-30 0001327273 lyra:TwentyThousandTwentyIncentiveAwardPlanMember 2021-01-01 2021-01-31 0001327273 srt:MinimumMember 2021-01-01 2021-06-30 0001327273 srt:MaximumMember 2021-01-01 2021-06-30 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001327273 lyra:MilestoneBasedAwardsMember 2021-04-01 2021-06-30 0001327273 lyra:MilestoneBasedAwardsMember 2020-04-01 2020-06-30 0001327273 lyra:MilestoneBasedAwardsMember 2021-01-01 2021-06-30 0001327273 lyra:MilestoneBasedAwardsMember 2020-01-01 2020-06-30 0001327273 2020-01-01 2020-12-31 0001327273 lyra:RevenueBasedMilestoneAwardsMember 2021-06-30 0001327273 lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember 2020-04-30 0001327273 lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember 2020-04-01 2020-04-30 0001327273 2017-11-01 2017-11-30 0001327273 us-gaap:LetterOfCreditMember 2017-11-30 0001327273 us-gaap:CertificatesOfDepositMember 2017-11-30 utr:sqft 0001327273 lyra:OfficeAndLaboratoryMember 2007-08-31 0001327273 us-gaap:OfficeEquipmentMember 2021-01-01 2021-06-30 0001327273 lyra:ClinicalSupplyAgreementMember 2021-04-30 0001327273 lyra:ClinicalSupplyAgreementMember 2021-05-31 2021-05-31 0001327273 2021-05-31 0001327273 lyra:ClinicalSupplyAgreementMember 2021-06-30 0001327273 lyra:ClinicalSupplyAgreementMember 2021-01-01 2021-06-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021  

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number: 001-39273

 

Lyra Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

84-1700838

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

480 Arsenal Way

Watertown, MA

02472

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617393-4600

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

LYRA

 

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.       Yes  ☒    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232. 405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes         No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  

As of August 2, 2021, the registrant had 13,001,105 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward looking statements, including but not limited to statements regarding:

 

our plans to develop and commercialize our product candidates;

 

the timing of our ongoing or planned clinical trials for LYR-210, LYR-220, and any future product candidates;

 

the timing of and our ability to obtain and maintain regulatory approvals for LYR-210, LYR-220, and any future product candidates;

 

the clinical utility of our product candidates;

 

our commercialization, marketing, and manufacturing capabilities and strategy;

 

our expectations about the willingness of healthcare professionals to use LYR-210, LYR-220, and any future product candidates;

 

our expectations regarding the development and commercialization of LYR-210 pursuant to the terms of the LianBio License Agreement;

 

our intellectual property position;

 

our competitive position and developments and projections relating to our competitors or our industry;

 

our ability to identify, recruit, and retain key personnel;

 

the impact of laws and regulations;

 

risks associated with the COVID-19 pandemic, which may adversely impact our business and clinical trials;

 

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act;

 

our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives;

 

our estimates and statements regarding our future revenue, future results of operations, and financial position;

 

our business strategy;

 

our research and development costs; and

 

the plans and objectives of management for future operations.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

 


In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, would,’or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Quarterly Report on Form 10-Q entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

 

 

 


 

Summary Risk Factors

Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:

 

we have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future viability;

 

we have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future, and we may never achieve profitability;

 

we will need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved;

 

our business is highly dependent on the success of our most advanced product candidate, LYR-210, which will require significant additional clinical testing before we can seek regulatory approval and potentially launch commercial sales, and if LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed;

 

managing our obligations under our license and other strategic agreements may divert management time and attention, causing delays or disruptions to our business;

 

our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities;

 

failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions;

 

we have entered into a collaboration agreement, and may enter into other collaboration agreements, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential;

 

clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired;

 

developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets;

 

the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies, and the failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue;

 

even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success;

 

we will rely on third parties for the manufacture of materials for our research programs, pre-clinical studies and clinical trials and we do not have long-term contracts with any of these parties, which increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts;

 

we rely on third parties to conduct our pre-clinical studies and clinical trials, and any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates;

 


 

if we are unable to obtain, maintain or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets;

 

if we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may materially suffer; and

 

the pandemic caused by COVID-19 could adversely impact our business and operations, including our clinical trials.

 

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

2

Item 1.

Condensed Consolidated Financial Statements (unaudited)

2

 

Condensed Consolidated Balance Sheets

2

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

3

 

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

4

 

Condensed Consolidated Statements of Cash Flows

6

 

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

30

Item 4.

Controls and Procedures

30

PART II.

OTHER INFORMATION

31

Item 1.

Legal Proceedings

31

Item 1A.

Risk Factors

31

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

87

Item 3.

Defaults Upon Senior Securities

87

Item 4.

Mine Safety Disclosures

87

Item 5.

Other Information

87

Item 6.

Exhibits

88

Signatures

89

 

 

 


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

 

LYRA THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)

 

 

 

June 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

69,046

 

 

$

74,593

 

Prepaid expenses and other current assets

 

 

1,027

 

 

 

1,324

 

Total current assets

 

 

70,073

 

 

 

75,917

 

Property and equipment, net

 

 

3,853

 

 

 

2,165

 

Operating lease right-of-use assets

 

 

1,834

 

 

 

2,301

 

Restricted cash

 

 

329

 

 

 

329

 

Other assets

 

 

243

 

 

 

118

 

Total assets

 

$

76,332

 

 

$

80,830

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,899

 

 

$

922

 

Accrued expenses and other current liabilities

 

 

2,976

 

 

 

2,977

 

Operating lease liabilities

 

 

1,029

 

 

 

985

 

Total current liabilities

 

 

5,904

 

 

 

4,884

 

Operating lease liabilities, net of current portion

 

 

929

 

 

 

1,454

 

Deferred revenue

 

 

12,000

 

 

 

 

Total liabilities

 

 

18,833

 

 

 

6,338

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized at

   June 30, 2021 and December 31, 2020; 13,001,105 and 12,932,377 shares issued and

   outstanding at June 30, 2021 and December 31, 2020, respectively

 

 

13

 

 

 

13

 

Additional paid-in capital

 

 

226,211

 

 

 

224,363

 

Accumulated deficit

 

 

(168,725

)

 

 

(149,884

)

Total stockholders’ equity

 

 

57,499

 

 

 

74,492

 

Total liabilities and stockholders’ equity

 

$

76,332

 

 

$

80,830

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

2


LYRA THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share data)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

7,505

 

 

$

2,103

 

 

$

12,275

 

 

$

5,067

 

General and administrative

 

 

3,560

 

 

 

2,442

 

 

 

6,621

 

 

 

3,726

 

Total operating expenses

 

 

11,065

 

 

 

4,545

 

 

 

18,896

 

 

 

8,793

 

Loss from operations

 

 

(11,065

)

 

 

(4,545

)

 

 

(18,896

)

 

 

(8,793

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

26

 

 

 

5

 

 

 

55

 

 

 

21

 

Total other income

 

 

26

 

 

 

5

 

 

 

55

 

 

 

21

 

Net loss

 

$

(11,039

)

 

$

(4,540

)

 

$

(18,841

)

 

$

(8,772

)

Comprehensive loss

 

$

(11,039

)

 

$

(4,540

)

 

$

(18,841

)

 

$

(8,772

)

Net loss per share attributable to common stockholders—basic and

   diluted

 

$

(0.85

)

 

$

(0.56

)

 

$

(1.45

)

 

$

(2.11

)

Weighted-average common shares outstanding—basic and diluted

 

 

12,991,837

 

 

 

8,182,725

 

 

 

12,968,820

 

 

 

4,206,793

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

3


 

 

LYRA THERAPEUTICS, INC.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(unaudited)

(in thousands, except share amounts)

 

 

Three Months Ended June 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Value

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Equity (Deficit)

 

Balance at March 31, 2020

 

 

287,426,285

 

 

$

160,197

 

 

 

 

230,860

 

 

$

 

 

$

5,208

 

 

$

(131,989

)

 

$

(126,781

)

Accretion of convertible preferred stock to

   redemption value

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

 

(30

)

 

 

 

 

 

(30

)

Conversion of redeemable convertible

   preferred stock to common stock upon

   closing of initial public offering

 

 

(287,426,285

)

 

 

(160,227

)

 

 

 

8,335,248

 

 

 

8

 

 

 

160,219

 

 

 

 

 

 

160,227

 

Issuance of common stock from initial

   public offering, net of issuance

   costs of $7,072

 

 

 

 

 

 

 

 

 

4,025,000

 

 

 

4

 

 

 

57,324

 

 

 

 

 

 

57,328

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

 

19,661

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of

   warrants

 

 

 

 

 

 

 

 

 

313,794

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

619

 

 

 

 

 

 

619

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,540

)

 

 

(4,540

)

Balance at June 30, 2020

 

 

 

 

$

 

 

 

 

12,924,563

 

 

$

13

 

 

$

223,339

 

 

$

(136,529

)

 

$

86,823

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2021

 

 

 

 

$

 

 

 

 

12,962,768

 

 

$

13

 

 

$

225,224

 

 

$

(157,686

)

 

$

67,551

 

Exercise of common stock options

 

 

 

 

 

 

 

 

 

38,337

 

 

 

 

 

 

331

 

 

 

 

 

 

331

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

656

 

 

 

 

 

 

656

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,039

)

 

 

(11,039

)

Balance at June 30, 2021

 

 

 

 

$

 

 

 

 

13,001,105

 

 

$

13

 

 

$

226,211

 

 

$

(168,725

)

 

$

57,499

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4


 

 

Six Months Ended June 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable

Convertible

Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Value

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Equity (Deficit)

 

Balance at December 31, 2019

 

 

209,119,674

 

 

$

130,666

 

 

 

 

230,860

 

 

$

 

 

$

4,419

 

 

$

(127,757

)

 

$

(123,338

)

Issuance of Series C redeemable convertible

   preferred stock, net of issuance costs

   of $201

 

 

78,306,611

 

 

 

29,446

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accretion of convertible preferred stock to

   redemption value

 

 

 

 

 

115

 

 

 

 

 

 

 

 

 

 

(115

)

 

 

 

 

 

(115

)

Issuance of common stock warrants in

   conjunction with sale of Series C

   redeemable convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

740

 

 

 

 

 

 

740

 

Conversion of redeemable convertible

   preferred stock to common stock

   upon closing of initial public offering

 

 

(287,426,285

)

 

 

(160,227

)

 

 

 

8,335,248

 

 

 

8

 

 

 

160,219

 

 

 

 

 

 

160,227

 

Issuance of common stock from initial

   public offering, net of issuance

   costs of $7,072

 

 

 

 

 

 

 

 

 

4,025,000

 

 

 

4

 

 

 

57,324

 

 

 

 

 

 

57,328

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

 

19,661

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of

   warrants

 

 

 

 

 

 

 

 

 

313,794

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

753

 

 

 

 

 

 

753

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,772

)

 

 

(8,772

)

Balance at June 30, 2020

 

 

 

 

$

 

 

 

 

12,924,563

 

 

$

13

 

 

$

223,339

 

 

$

(136,529

)

 

$

86,823

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020

 

 

 

 

$

 

 

 

 

12,932,377

 

 

$

13

 

 

$

224,363

 

 

$

(149,884

)

 

$

74,492

 

Exercise of common stock options

 

 

 

 

 

 

 

 

 

68,728

 

 

 

 

 

 

593

 

 

 

 

 

 

593

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,255

 

 

 

 

 

 

1,255

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,841

)

 

 

(18,841

)

Balance at June 30, 2021

 

 

 

 

$

 

 

 

 

13,001,105

 

 

$

13

 

 

$

226,211

 

 

$

(168,725

)

 

$

57,499

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

5


 

 

LYRA THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(18,841

)

 

$

(8,772

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

1,255

 

 

 

753

 

Depreciation expense

 

 

373

 

 

 

21

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

297

 

 

 

(2,400

)

Operating lease right-of-use assets

 

 

467

 

 

 

440

 

Accounts payable

 

 

743

 

 

 

138

 

Accrued expenses and other current liabilities

 

 

(22

)

 

 

(1,237

)

Operating lease liabilities

 

 

(481

)

 

 

(438

)

Deferred revenue

 

 

12,000

 

 

 

 

Net cash used in operating activities

 

 

(4,209

)

 

 

(11,495

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(1,785

)

 

 

(85

)

Net cash used in investing activities

 

 

(1,785

)

 

 

(85

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from the sale of Series C redeemable convertible preferred stock

 

 

 

 

 

30,392

 

Payment of offering costs related to sale of Series C redeemable convertible preferred

   stock

 

 

 

 

 

(205

)

Proceeds from initial public offering, net of underwriting discounts

 

 

 

 

 

59,892

 

Payment of initial public offering costs

 

 

 

 

 

(1,708

)

Payment of deferred offering expenses

 

 

(146

)

 

 

 

Proceeds from exercise of stock options

 

 

593

 

 

 

 

Net cash provided by financing activities

 

 

447

 

 

 

88,371

 

Net (decrease) increase in cash and cash equivalents

 

 

(5,547

)

 

 

76,791

 

Cash and cash equivalents and restricted cash, beginning of period

 

 

74,922

 

 

 

10,137

 

Cash and cash equivalents and restricted cash, end of period

 

$

69,375

 

 

$

86,928

 

Supplemental disclosure of non-cash financing and investing activities:

 

 

 

 

 

 

 

 

Property and equipment purchases included in accounts payable

 

$

363

 

 

$

30

 

Conversion of redeemable convertible preferred stock

 

$

 

 

$

160,227

 

Allocation of Series C redeemable convertible preferred stock to common stock warrant

 

$

 

 

$

740

 

Series C redeemable convertible preferred stock stock issuance costs

    included in accounts payable and accrued expense

 

$

 

 

$

1

 

Accretion of redeemable convertible preferred stock to redemption value